About Tandem Diabetes Care, Inc. - Common Stock (TNDM)
Tandem Diabetes Care is a medical device company that specializes in the development and manufacturing of innovative products for people with diabetes. The company focuses on creating advanced insulin delivery systems, including insulin pumps and related software solutions, designed to improve the management of diabetes for individuals who rely on insulin therapy. By leveraging cutting-edge technology, Tandem aims to enhance the user experience, offering features such as automated insulin delivery and seamless data integration, ultimately helping patients achieve better health outcomes and greater convenience in their daily lives. Read More
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Tandem Diabetes’ third quarter was marked by improved operational efficiency and commercial execution, resulting in a positive market reaction. Management credited the quarter’s performance to the ongoing modernization of U.S. commercial operations, increased pricing contributions from both traditional and pharmacy channels, and early traction from new product offerings. CEO John Sheridan highlighted that changes in sales processes and organizational restructuring began to yield tangible results, particularly through better sales productivity and a strong mix of customers adopting both t:slim and Mobi pump platforms. The company’s focus on expanding pharmacy benefit access and a growing portfolio approach helped offset volume headwinds and supported margin improvements.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board’s Audit Committee and Cybersecurity and Data Oversight Committee.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Android version of the Tandem Mobi mobile app.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
jumped 20.3% in the afternoon session after the company reported third-quarter results that surpassed analyst expectations for both revenue and earnings per share.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 2.6% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates.
Tandem Diabetes Care (TNDM) beat Q3 2025 earnings and revenue estimates, driving a 16% stock surge. The company reported strong sales growth and improved margins.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 2.2% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 5.1% in the morning session after analyst projections for its third-quarter 2025 earnings pointed to a year-on-year revenue decline.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achieved ISO/IEC 27001:2022 Certification from Insight Assurance, affirming Tandem’s company-wide commitment to cybersecurity, data protection, and operational integrity. As Tandem continues to expand internationally, the ISO/IEC 27001:2022 certification strengthens its position in regulated markets and simplifies compliance for partners and healthcare providers worldwide.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 6% in the afternoon session after investor concerns were sparked by a disappointing financial outlook from peer DexCom. DexCom, a major company in the glucose monitoring market, reported its third-quarter financial results. Although the company's earnings and revenue surpassed targets, its stock fell sharply by around 11% to 12%. The drop was triggered after company executives provided a growth forecast for 2026 that might not meet Wall Street's expectations and also signaled a lower margin forecast. This negative outlook from a key industry player appeared to create wider concerns, weighing on shares of related companies like Tandem Diabetes.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:
